Asep Medical Holdings Inc (SEPSF)
USD 0.39
(0.0%)
USD 0.39
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 7.74 Million CAD | 18.47% |
| 2022 | 5.44 Million CAD | 175.21% |
| 2021 | 1.97 Million CAD | 120047.33% |
| 2020 | 1646.00 CAD | -74.73% |
| 2019 | 6513.00 CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 663.64 Thousand CAD | -57.72% |
| 2024 Q2 | 1.06 Million CAD | 103.84% |
| 2023 FY | 6.44 Million CAD | 18.47% |
| 2023 Q3 | 1.59 Million CAD | -23.9% |
| 2023 Q2 | 2.09 Million CAD | 26.25% |
| 2023 Q1 | 1.65 Million CAD | 34.89% |
| 2023 Q4 | 1.56 Million CAD | -1.4% |
| 2022 Q2 | 1.5 Million CAD | -3.41% |
| 2022 Q1 | 1.56 Million CAD | 37.3% |
| 2022 FY | 5.44 Million CAD | 175.21% |
| 2022 Q4 | 1.22 Million CAD | 7.09% |
| 2022 Q3 | 1.14 Million CAD | -23.89% |
| 2021 Q2 | 97.91 Thousand CAD | 6.36% |
| 2021 FY | 1.97 Million CAD | 120047.33% |
| 2021 Q1 | 92.05 Thousand CAD | 0.0% |
| 2021 Q4 | 1.13 Million CAD | 406.89% |
| 2021 Q3 | 224.18 Thousand CAD | 128.96% |
| 2020 FY | 1646.00 CAD | -74.73% |
| 2019 FY | 6513.00 CAD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bioxytran, Inc. | 3.82 Million USD | -102.673% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 91.079% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -2858.209% |
| SQZ Biotechnologies Company | 85.61 Million USD | 90.957% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -165.493% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 73.802% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 79.218% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -415.508% |
| Marizyme, Inc. | 19.23 Million USD | 59.758% |
| Genus plc | 147.7 Million USD | 94.758% |
| Pharming Group N.V. | 225.49 Million USD | 96.566% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -277.917% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -477.126% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 7.154% |
| ContraFect Corporation | 56.88 Million USD | 86.39% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -423.577% |
| IMV Inc. | 37.7 Million USD | 79.468% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -177.47% |
| ONE Bio Corp. | 6.44 Million USD | -20.151% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 90.991% |
| Mesoblast Limited | 5.9 Million USD | -31.183% |
| MultiCell Technologies, Inc. | 567.42 USD | -1364392.439% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 68.673% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.062% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -1887.443% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -194.666% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -57.433% |
| Biomind Labs Inc. | 994.18 Thousand USD | -678.771% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -339.99% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -15.248% |
| Skye Bioscience, Inc. | 13.54 Million USD | 42.85% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -315.283% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 11.81% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 31069.612% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -75.618% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -53.557% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 51.641% |
| Accustem Sciences Inc. | 3.74 Million USD | -106.661% |
| EV Biologics, Inc. | 531.96 Thousand USD | -1355.443% |
| Q BioMed Inc. | 3.43 Million USD | -125.291% |
| GB Sciences, Inc. | 1.42 Million USD | -445.044% |
| Alpha Cognition Inc. | 9.7 Million USD | 20.227% |
| CSL Limited | 3.44 Billion USD | 99.776% |
| Agentix Corp. | 1.37 Million USD | -464.415% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 92.205% |
| Enzolytics Inc. | 2.17 Million USD | -255.236% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | 12.71 Million USD | 39.094% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -112.08% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -321.907% |
| argenx SE | 1.53 Billion USD | 99.495% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 86.521% |
| HST Global, Inc. | 140.9 Thousand USD | -5394.69% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -641.609% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -588.269% |
| Halberd Corporation | 74.84 Thousand USD | -10244.997% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -221.938% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -127.385% |
| Zenith Capital Corp. | 8.94 Million USD | 13.425% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -390.226% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -215.332% |
| AVAX Technologies, Inc. | 7.31 Million USD | -5.911% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -4414.284% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -303.06% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -44342.931% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 2.46 Million USD | -213.869% |
| Helix BioMedix, Inc. | 1.97 Million USD | -292.61% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 28.753% |
| Kadimastem Ltd | 2.41 Million USD | -221.247% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 22.97 Million USD | 66.3% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -4166.139% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -479.768% |
| LadRx Corporation | 3.81 Million USD | -103.117% |
| Cell Source, Inc. | 4.32 Million USD | -79.001% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -1763.488% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -738.367% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -738.367% |
| Affymax, Inc. | 39.38 Million USD | 80.342% |
| Mobile Lads Corp. | 554.54 Thousand USD | -1296.17% |
| Itoco Inc. | 919.14 Thousand USD | -742.35% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -82.672% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -591.904% |
| International Stem Cell Corporation | 5.27 Million USD | -46.887% |
| CytoDyn Inc. | 18.05 Million USD | 57.125% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -30661.663% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -3418.027% |
| Qrons Inc. | 643.67 Thousand USD | -1102.84% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -445.32% |
| SYBLEU INC | 160.87 Thousand USD | -4712.653% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | -247.212% |
| Rebus Holdings, Inc. | 664 Thousand USD | -1066.025% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -326.269% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -14607.654% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -37959.298% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 78.651% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -378.517% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -952.193% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -148.872% |
| Neutra Corp. | 243.82 Thousand USD | -3075.446% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 55.649% |
| PureTech Health plc | 144.59 Million USD | 94.646% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 62.214% |
| IXICO plc | 4.7 Million USD | -64.487% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 11.988% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 93.425% |
| CSL Limited | 3.89 Billion USD | 99.801% |
| Cellectis S.A. | 97.32 Million USD | 92.044% |